- Home
- BEATW vs NRXS Comparison
BEATW vs NRXS Comparison
Compare BEATW & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEATW
- NRXS
- Stock Information
- Founded
- BEATW 2015
- NRXS 2011
- Country
- BEATW United States
- NRXS United States
- Employees
- BEATW 20
- NRXS N/A
- Industry
- BEATW Retail: Computer Software & Peripheral Equipment
- NRXS
- Sector
- BEATW Technology
- NRXS
- Exchange
- BEATW Nasdaq
- NRXS Nasdaq
- Market Cap
- BEATW N/A
- NRXS N/A
- IPO Year
- BEATW N/A
- NRXS 2023
- Fundamental
- Price
- BEATW $0.51
- NRXS $2.15
- Analyst Decision
- BEATW
- NRXS
- Analyst Count
- BEATW 0
- NRXS 0
- Target Price
- BEATW N/A
- NRXS N/A
- AVG Volume (30 Days)
- BEATW 4.7K
- NRXS 19.0K
- Earning Date
- BEATW 03-14-2025
- NRXS 03-20-2025
- Dividend Yield
- BEATW N/A
- NRXS N/A
- EPS Growth
- BEATW N/A
- NRXS N/A
- EPS
- BEATW N/A
- NRXS N/A
- Revenue
- BEATW N/A
- NRXS $2,685,925.00
- Revenue This Year
- BEATW N/A
- NRXS N/A
- Revenue Next Year
- BEATW N/A
- NRXS N/A
- P/E Ratio
- BEATW N/A
- NRXS N/A
- Revenue Growth
- BEATW N/A
- NRXS 9.18
- 52 Week Low
- BEATW $0.50
- NRXS $1.99
- 52 Week High
- BEATW $0.62
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- BEATW N/A
- NRXS 45.69
- Support Level
- BEATW N/A
- NRXS $2.01
- Resistance Level
- BEATW N/A
- NRXS $2.18
- Average True Range (ATR)
- BEATW 0.00
- NRXS 0.19
- MACD
- BEATW 0.00
- NRXS 0.00
- Stochastic Oscillator
- BEATW 0.00
- NRXS 32.23
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.